Cellectar Biosciences, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

STOCK-BASED COMPENSATION

Summary of the expense for stock-based compensation related to stock option grants


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2024			2023			2024			2023

Employee and director stock option grants:
Research and development		$	309,933		$	89,172		$	453,158		$	227,896
General and administrative			1,224,121			408,706			2,334,508			1,097,945
Total stock-based compensation		$	1,534,054		$	497,878		$	2,787,666		$	1,325,841


		Twelve Months Ended
		December 31,
		2023			2022
Employee and director stock option and stock grants:
Research and development		$	505,155		$	165,461
General and administrative			1,905,133			1,287,502
Total stock-based compensation		$	2,410,288		$	1,452,964